Neutropenic sepsis: prevention and management in people with cancer - National Institute for Health and Care Excellence (NICE)
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
- A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with cancer. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.
- Fluoroquinolone antibiotics: In January 2020, we updated this guideline to reflect MHRA restrictions and precautions for the use of fluoroquinolone antibiotics following rare reports of disabling and potentially long-lasting or irreversible side effects (see Drug Safety Update and update information for details).